Anti-GD2 chimeric antigen receptor (CAR)-modified T cells may be a new and innovative approach for the treatment of pediatric H3-K27M-mutant diffuse midline gliomas.
This is a preview of subscription content, log in via an institution to check access.
References
Jones, C. & Baker, S. J. Nat. Rev. Cancer 14, 651–661 (2014).
Mackay, A. et al. Cancer Cell 32, 520–537 (2017).
Lewis, P. W. et al. Science 340, 857–861 (2013).
Mount, C. W. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0006-x (2018).
Maude, S. L. et al. N. Engl. J. Med. 378, 439–448 (2018).
Ahmed, N. et al. JAMA Oncol. 3, 1094–1101 (2017).
O’Rourke, D. M. et al. Sci. Transl. Med. 9, eaaa0984 (2017).
Brown, C. E. et al. N. Engl. J. Med. 375, 2561–2569 (2016).
Yu, A. L. et al. N. Engl. J. Med. 363, 1324–1334 (2010).
Waligora, M. et al. PLoS Med. 15, e1002505 (2018).
Grasso, C. S. et al. Nat. Med. 21, 827 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Ramaswamy, V., Taylor, M.D. CAR T cells for childhood diffuse midline gliomas. Nat Med 24, 534–535 (2018). https://doi.org/10.1038/s41591-018-0031-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-018-0031-9
- Springer Nature America, Inc.